2101765-83-5
2101765-83-5
Chemical Structure
DRI-C25441
- CAS No.: 2101765-83-5
- Formula:C31H21N3O6
- Molecular Weight:531.51
IUPAC Name: 4-(4'-(4-nitrobenzamido)-[1,1'-biphenyl]-4-carboxamido)-1-naphthoic acid
InChIKey: LZHHABGKCSZVBE-UHFFFAOYSA-N
SMILES: O=C(C1=C2C=CC=CC2=C(NC(C3=CC=C(C4=CC=C(NC(C5=CC=C([N+]([O-])=O)C=C5)=O)C=C4)C=C3)=O)C=C1)O
Biological Activity: DRI-C25441 is a potent blocker of CD40 and CD40L interaction, with an IC50 of 0.36 μM. DRI-C25441 can inhibit the immune response induced by alloantigen. can inhibit CD40L induced activation of NF-κB signaling pathway. DRI-C25441 commonly is used in research on immune conditions [1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DRI-C25441 | 98.67% | DRI-C25441 is a potent blocker of CD40 and CD40L interaction, with an IC50 of 0.36 μM. DRI-C25441 can inhibit the immune response induced by alloantigen. can inhibit CD40L induced activation of NF-κB signaling pathway. DRI-C25441 commonly is used in research on immune conditions . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.73
HY-154821DRI-C21041 -
Similarity Score 0.66
HY-120323DRI-C21045 -
Similarity Score 0.58
![N4,N4'-Di(pyridin-4-yl)-[1,1'-biphenyl]-4,4'-dicarboxamide Chemical Structure](//file.medchemexpress.com/product_pic/hy-w243985.gif)
HY-W243985N4,N4'-Di(pyridin-4-yl)-[1,1'-biphenyl]-4,4'-dicarboxamide -
Similarity Score 0.58
HY-19753KS176 -
Similarity Score 0.57
HY-184489PGP/FSP1-IN-1 -
Similarity Score 0.57
HY-W10498954,4'-(1,4-Phenylene)bis(1-naphthoic acid) -
Similarity Score 0.57
HY-120130BMS-948 -
Similarity Score 0.57
HY-178520BAS00132635 -
Similarity Score 0.57
HY-125961T3Inh-1 -
Explore the MedChemAI to find more analogs
![N4,N4'-Di(pyridin-4-yl)-[1,1'-biphenyl]-4,4'-dicarboxamide Chemical Structure](http://file.medchemexpress.com/product_pic/hy-w243985.gif)
References
- [1]. Lu H, et, al. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther. 2020 Sep 23;5(1):213. [Content Brief]
- [2]. Chen J, et al. Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction. J Med Chem. 2017 Nov 9;60(21):8906-8922. [Content Brief]
